Article
Plasminogen activator inhibitor-1 polymorphisms (-844 G>A and HindIII C>G) in systemic lupus erythematosus: Association with clinical variables
Fecha
2012Registro en:
10.1007/s10238-010-0099-0
Autor
Cambon, A.
Barbosa, S.
Rey-Rico, A.
Figueroa-Ochoa, E.B.
Soltero, J.F.A.
Yeates, S.G.
Alvarez-Lorenzo, C.
Concheiro, A.
Taboada, P.
Mosquera, V.
Institución
Resumen
Two new poly(ethylene oxide)-poly(styrene oxide) triblock copolymers (PEO-PSO-PEO) with optimized block lengths selected on the basis of previous studies were synthesized with the aim of achieving a maximal solubilization ability and a suitable sustained release, while keeping very low material expense and excellent aqueous copolymer solubility. The self-assembling and gelling properties of these copolymers were characterized by means of light scattering, fluorescence spectroscopy, transmission electron microscopy, and rheometry. Both copolymers formed spherical micelles (12-14nm) at very low concentrations. At larger concentration (>25wt%), copolymer solutions showed a rich phase behavior, with the appearance of two types of rheologically active (more viscous) fluids and of physical gels depending on solution temperature and concentration. The copolymer behaved notably different despite their relatively similar block lengths. The ability of the polymeric micellar solutions to solubilize the antifungal drug griseofulvin was evaluated and compared to that reported for other structurally-related block copolymers. Drug solubilization values up to 55mgg-1 were achieved, which are greater than those obtained by previously analyzed poly(ethylene oxide)-poly(styrene oxide), poly(ethylene oxide)-poly(butylene oxide), and poly(ethylene oxide)-poly(propylene oxide) block copolymers. The results indicate that the selected SO/EO ratio and copolymer block lengths were optimal for simultaneously achieving low critical micelle concentrations (cmc) values and large drug encapsulation ability. The amount of drug released from the polymeric micelles was larger at pH 7.4 than at acidic conditions, although still sustained over 1day. " 2012 Elsevier Inc.",,,,,,"10.1016/j.jcis.2012.06.090",,,"http://hdl.handle.net/20.500.12104/43692","http://www.scopus.com/inward/record.url?eid=2-s2.0-84866630016&partnerID=40&md5=69a9d72eecfd7d43e6968349e18faf7f",,,,,,"1",,"Journal of Colloid and Interface Science",,"275 284",,"387",,"Scopus WOS",,,,,,"Block copolymer; Drug delivery system; Phase behavior; Polymeric micelle; Release kinetics",,,,,,"Poly(ethylene oxide)-poly(styrene oxide)-poly(ethylene oxide) copolymers: Micellization, drug solubilization, and gelling features",,"Article"
"45454","123456789/35008",,"Urzúa, G.A., University of Guadalajara, Guadalajara, Mexico; Bores, L.D., 16857 E. Saguaro Blvd., Fountain Hills, AZ 85268, United States, Ophthalmic International, Fountain Hills, AZ, United States; Livecchi, J.T., Drexel Univ. College of Medicine, Philadelphia, PA, United States, Coronado Industries, Fountain Hills, AZ, United States",,"Urzua, G.A. Bores, L.D. Livecchi, J.T.",,"2005",,"Pneumatic trabeculoplasty (PNT), when used in combination with antiglaucoma medication, was evaluated in two studies: a feasibility study involving 177 patients, and a separate efficacy study involving 317 eyes. Both studies were nonblinded, single-armed, and nonrandomized; the primary efficacy end point in each study was a decrease in intraocular pressure (IOP) compared with baseline. The first study reported a mean drop in IOP of 6.3 mmHg across the entire group. The second study showed a mean IOP after PNT treatment level at least 1 mmHg less than the pretreatment mean; except at 3, 6, 9, and 12 months, when it was at least 2 mmHg less than the initial mean IOP. The lesser reduction observed in the second study can be explained by the fact that a number of the patients were at least partially controlled by antiglaucoma medications at enrollment, and, as a result, the group had a lower starting IOP than those enrolled in the first study. In both studies, a clear trend to less medication was observed when PNT was added to a patient's treatment regime. The ability of PNT to reduce IOP and medication requirements, along with its relatively benign safety profile, supports the use of PNT as part of a glaucoma patient's treatment regimen.",,,,,,,,,"http://hdl.handle.net/20.500.12104/43675","http://www.scopus.com/inward/record.url?eid=2-s2.0-18044393603&partnerID=40&md5=b979df656d020f75985a79e562b86a5b",,,,,,"1",,"Annals of Ophthalmology",,"37 46",,"37",,"Scopus WOS",,,,,,,,,,,,"Pneumatic trabeculoplasty: A new method to treat primary open-angle glaucoma and reduce the number of concomitant medications",,"Article"
"45459","123456789/35008",,"Flores, J.L., Electronic Engineering Department, University of Guadalajara, Av. Revolución #1500, Guadalajara, Jal., CP, 44430, Mexico; Montoya, M.; García-Torales, G., Electronic Engineering Department, University of Guadalajara, Av. Revolución #1500, Guadalajara, Jal., CP, 44430, Mexico; Álvarez, A.G., Chemical Engineering Department, University of Guadalajara, B. Marcelino García Barragan #1451, Guadalajara, Jal., CP. 44430, Mexico",,"Flores, J.L. Montoya, M. García-Torales, G. Alvarez, A.G.",,"2005",,"A polarimeter designed for measuring small rotation angles on the polarization plane of light is described. The experimental device employs one fixed polarizer and a rotating analyzer. The system generates a periodical intensity signal, which is then Fourier analyzed. The coefficients of Fourier Transform contain information about rotation angles produced by organic compounds that exhibited optical activity. The experimental device can be used to determine the sugar concentration in agave juice. Polarimetry, glucose.",,,,,,"10.1117/12.617975",,,"http://hdl.handle.net/20.500.12104/43680","http://www.scopus.com/inward/record.url?eid=2-s2.0-29144533499&partnerID=40&md5=2ec38e5726a14503056324399865681e",,,,,,,,"Proceedings of SPIE - The International Society for Optical Engineering",,"1 7",,"5875",,"Scopus",,,,,,,,,,,,"Polarimeter with linear response for measuring optical activity in organic compounds",,"Conference Paper"
"45443","123456789/35008",,"Padilla-Gutiérrez, J.R., Departamento de Biología Molecular y Genómica, Instituto de Investigacion en Reumatologia y Del Sistema Musculo Esqueletico, Universidad de Guadalajara, Insurgentes 244-1, Colonia Lomas de Atemajac, Zapopan, Jalisco 45178, Mexico, Posdoctoral Fellow in Biomedical Sciences (Immunology). Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Palafox-Sánchez, C.A., Departamento de Biología Molecular y Genómica, Instituto de Investigacion en Reumatologia y Del Sistema Musculo Esqueletico, Universidad de Guadalajara, Insurgentes 244-1, Colonia Lomas de Atemajac, Zapopan, Jalisco 45178, Mexico; Valle, Y., Departamento de Biología Molecular y Genómica, Instituto de Investigacion en Reumatologia y Del Sistema Musculo Esqueletico, Universidad de Guadalajara, Insurgentes 244-1, Colonia Lomas de Atemajac, Zapopan, Jalisco 45178, Mexico, Posdoctoral Fellow in Biomedical Sciences (Immunology). Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Orozco-Barocio, G., Departamento de Inmunología y Reumatología Del Hospital General de Occidente, Secretaría de Salud Jalisco, Av. Zoquipan 1050, Zapopan, Jalisco 45100, Mexico; Oregón-Romero, E., Departamento de Biología Molecular y Genómica, Instituto de Investigacion en Reumatologia y Del Sistema Musculo Esqueletico, Universidad de Guadalajara, Insurgentes 244-1, Colonia Lomas de Atemajac, Zapopan, Jalisco 45178, Mexico; Vázquez-Del Mercado, M., Departamento de Biología Molecular y Genómica, Instituto de Investigacion en Reumatologia y Del Sistema Musculo Esqueletico, Universidad de Guadalajara, Insurgentes 244-1, Colonia Lomas de Atemajac, Zapopan, Jalisco 45178, Mexico; Rangel-Villalobos, H., Instituto de Investigación en Genética Molecular, Centro Universitario de la Ciénega, Universidad de Guadalajara, Ocotlán, Jalisco, Mexico; Llamas-Covarrubias, M.A., Departamento de Biología Molecular y Genómica, Instituto de Investigacion en Reumatologia y Del Sistema Musculo Esqueletico, Universidad de Guadalajara, Insurgentes 244-1, Colonia Lomas de Atemajac, Zapopan, Jalisco 45178, Mexico; Muñoz-Valle, J.F., Departamento de Biología Molecular y Genómica, Instituto de Investigacion en Reumatologia y Del Sistema Musculo Esqueletico, Universidad de Guadalajara, Insurgentes 244-1, Colonia Lomas de Atemajac, Zapopan, Jalisco 45178, Mexico",,"Padilla-Gutierrez, J.R. Palafox-Sanchez, C.A. Valle, Y. Orozco-Barocio, G. Oregon-Romero, E. Vazquez-Del Mercado, M. Rangel-Villalobos, H. Llamas-Covarrubias, M.A. Munoz-Valle, J.F.",,"2011",,"Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by the presence of autoantibodies against nuclear autoantigens as well as cytoplasmic and circulating proteins. Recent studies have demonstrated mechanisms responsible for modulation of the immune response by the plasminogen activator inhibitor-1 (PAI-1). Furthermore, the endogenous PAI-1 has shown to promote a Th2 immune response. We assessed the -844 G>A and HindIII C>G PAI-1 polymorphisms in SLE. In a case-control study of 71 SLE patients classified according to ACR criteria and 71 healthy subjects (HS). The A allele of -844 PAI-1 polymorphism showed a significant difference in SLE patients (41%) when compared with HS (27%) [P = 0.01; OR = 1.8, 95%, CI = 1.1-3.0]. In addition, the -844 G>A PAI-1 polymorphism was associated with increased risk for SLE in a dominant genetic model (G/G vs. G/A + A/A; OR = 2.3, 95% CI = 1.14-4.44). Also, anti-RNP positive antibodies in SLE were associated with G/G -844 PAI-1 genotype. The HindIII polymorphism did not show any differences. The haplotype analysis showed that the AC haplotype confers susceptibility to SLE (OR = 3.1, 95% CI, 1.45-6.52; P = 0.003). The AC haplotype of the -844 and HindIII PAI-1 polymorphism might be an additional susceptibility factor to SLE in Mexicans. " 2010 Springer-Verlag.